Interestingly, in a previous transgenic mouse model, a combination of afatinib and bevacizumab effectively suppressed tumor bearing EGFR 19 deletion/T790M and L858R/T790M mutations compared to treatment by either drug alone [35]. The gene discussed is EGFR; the disease is neoplasm.